RT Journal Article SR Electronic T1 Prenatal smoking, alcohol and caffeine exposure and ADHD risk in childhood: parental comparisons and polygenic risk score (PRS) analyses JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.25.21254087 DO 10.1101/2021.03.25.21254087 A1 Elis Haan A1 Hannah M. Sallis A1 Luisa Zuccolo A1 Jeremy Labrecque A1 Eivind Ystrom A1 Ted Reichborn-Kjennerud A1 Ole Andreassen A1 Alexandra Havdahl A1 Marcus R. Munafò YR 2021 UL http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254087.abstract AB Background and aims Several studies have indicated that maternal prenatal substance use may be associated with offspring ADHD via intrauterine effects. We investigated associations between maternal prenatal smoking, alcohol and caffeine consumption with childhood ADHD risk accounting for shared familial factors.Design First, we used a negative control design comparing maternal and paternal substance use. Three models were used for negative control analyses: unadjusted (without confounders); adjusted (including confounders) and mutually adjusted (including confounders and partner’s substance use). The results were meta-analysed across the cohorts. Second, we used polygenic risk scores (PRS) as proxies for exposures. Maternal PRS for genetic variants of smoking, alcohol and coffee consumption were regressed against ADHD risk. We triangulated the results across the two approaches to infer causality.Setting We used data from three longitudinal pregnancy cohorts: Avon Longitudinal Study of Parents and Children (ALSPAC) in the UK, Generation R study (GenR) in the Netherlands and Norwegian Mother, Father and Child Cohort study (MoBa) in Norway.Participants Phenotype data available for children was: NALSPAC=7,850; NGENR=3,849; NMOBA=43,512. Genotype data available for mothers was: NALSPAC=7,074 and NMOBA=14,583.Measurements Offspring ADHD risk around age 7-8 was derived by dichotomising symptom scores from multiple questionnaires and parental self-reported substance use was measured at the 2nd pregnancy trimester.Findings The pooled estimate for maternal prenatal substance use showed an association with ADHD risk (ORSMOKING=1.11, 95%CI 1.00-1.23; ORALCOHOL=1.27, 95%CI 1.08-1.49; ORCAFFEINE=1.05, 95%CI 1.00-1.11), while not for fathers (ORSMOKING=1.03, 95%CI 0.95-1.13; ORALCOHOL=0.83, 95%CI 0.47-1.48; ORCAFFEINE=1.02, 95%CI 0.97-1.07). However, maternal associations did not persist in sensitivity analyses (substance use before pregnancy, adjustment for maternal ADHD in MoBa). The PRS analyses did not show evidence of association in ALSPAC or MoBa.Conclusions Our results do not provide support for a causal intrauterine effect of maternal prenatal substance use on offspring attention-deficit hyperactivity disorder risk.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/wxu58 Funding StatementThis research was performed in the UK Medical Research Council Integrative Epidemiology Unit (grant number MC UU 00011/7) and also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. LZ was supported by a UK Medical Research Council fellowship (grant number G0902144). HMS is supported by the European Research Council (Grant ref: 758813 MHINT). The South-Eastern Norway Regional Health Authority supported AH (2018059 & 2020022). The Norwegian Research Council supported EY (262177 & 288083), (OAA and RCN 273291 & 223273), TRK (274611) and AH (274611 & 288083). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. This research was also conducted as part of the CAPICE (Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe) project, funded by the European Unions Horizon 2020 research and innovation programme, Marie Sklodowska Curie Actions MSCA ITN 2016 Innovative Training Networks under grant agreement number 721567.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ALSPAC study was approved by the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees and informed consent for the use of data collected via questionnaires and clinics was obtained from participants The GenR study was approved by the local Medical Ethical Committee (MEC 198.782/2001/31). Written informed consent was obtained from all participating women The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics (2016/1702).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe informed consent obtained from ALSPAC participants does not allow the data to be made freely available through any third party maintained public repository. However, data used for this submission can be made available on request to the ALSPAC Executive. The ALSPAC data management plan describes in detail the policy regarding data sharing, which is through a system of managed open access. In MoBa, the consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should submit an application to datatilgang{at}fhi.no. Access to data sets requires approval from The Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa. In GenR, to ensure participant privacy and law compliance, individual-level data cannot be made publicly available without explicit informed consent, which is not available. For new analyses or individual-level data access, please contact Generation R data management (datamanagementgenr{at}erasmusmc.nl) http://www.bristol.ac.uk/alspac/researchers/access/ http://www.bristol.ac.uk/alspac/researchers/our-data/ https://generationr.nl/researchers/collaboration/